Anecortave Acetate Versus Placebo in AMD Patients Following PDT

Phase 2

Completed

• Conditions: AMD

• Registration Number: NCT00346866
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-05
• Primary Completion: 2001-12
• Study Completion: 2001-12
• Study First Submitted: 2006-06-28
• Study First Submitted QC: 2006-06-28
• Study First Posted: 2006-06-30
• Status Verified: 2008-08
• Last Update Submitted: 2008-08-04
• Last Update Posted: 2008-08-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

• AMD disease

Exclusion Criteria

• Age

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Mean change from the baseline in logMAR visual acuity score at Month 6

Secondary Outcome Measures

Name	Time	Method
% patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.

Trial Locations

Locations (1)

Facility; 🇺🇸 Beachwood, Ohio, United States